RBR-8s3qz5s招募中Unknown
An Implementation study of long-acting injectable cabotegravir (CAB-LA) for HIV Pre-Exposure Prophylaxis (PrEP) among young MSM, non-binary and transgender persons - ImPrEP CAB-LA Implementation study of long-acting injectable cabotegravir
Instituto Nacional de Infectologia Evandro Chagas - INI/Fiocruz0 个研究点开始时间: 2023年11月29日最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18Y 至 30Y（—）
入选标准
- •Cisgender, non-binary (assigned male at birth) or transvestite men, transgender men and women; Report of anal sex in the past six months with a person who was assigned male at birth (Persons born female who have had sex only with people born female are excluded); Age from 18 to 30 years old; Report to the study center looking for PrEP;
- •PrEP-naïve with CAB LA or oral PrEP with TDF/FTC; Willing and able to provide written informed consent and adhere to study requirements; Non-reactive/negative HIV test results, including rapid HIV tests and an undetectable HIV RNA test at enrollment for individuals who choose injectable CAB-LA; No reports of liver dysfunction. Applicants who report liver disease will have their enrollment visit postponed until laboratory results of liver function tests are available. See Section 7 (Study Procedures - Inclusion Visit); Willing to undergo all necessary study procedures.
排除标准
- •One or more reactive or positive HIV test results at the enrollment visit, even if HIV infection is not confirmed; Currently participating in a PrEP agent intervention trial, HIV vaccine trial, or experimental medication trial; Positive pregnancy test, breastfeeding or intent to become pregnant during study enrollment (for trans men); Previous participation in studies with Cabotegravir; History or presence of allergy to study drug components; Past participation in an HIV vaccine trial. An exception will be made for participants who can provide documentation of placebo receipt (non-active arm); Planning to relocate outside the area during the study period; Injected or surgically placed buttock implants or fillers, by self-report; Have a dermatological/inflammatory skin condition overlying the buttock region which, in the opinion of the study investigator, in consultation with the Clinical Study Coordination (CSC), may interfere with the interpretation of injection site reactions; Active or planned use of a contraindicated co-administered drug for which significant decreases in plasma concentrations of Cabotegravir may occur due to uridine diphosphate glucuronosyltransferase (UGT1A1): • Anticonvulsants: Carbamazepine, Oxcarbazepine, Phenobarbital, Phenytoin • Antimycobacterial: Rifampicin, Rifapentine; Current or anticipated need for chronic systemic anticoagulation or history of known or suspected bleeding disorder, including history of prolonged bleeding; History of severe liver failure (including, but not limited to, history of liver failure or hospitalization for liver disease, history of hepatocellular carcinoma or near liver transplant); Individuals with advanced Hepatitis C; Other medical conditions that, in the opinion of the study investigator, interfere with the conduct of the study (eg, provided by self-report or found by the physician).
研究者
相似试验
Unknown
3 期
Acceptability and Feasibility of long-acting INjectable ART in Adolescents and Young Adults.HIV/AIDSPACTR202402700796695Desmond Tutu Health Foundation200
招募中
4 期
TOXSIALO-TRIAL : Evaluation of the long-term efficacy of the injection of botulinum toxin A into the salivary glands versus scopolamine patches in the treatment of drooling in children over 4 years old with cerebral palsy.2024-512160-58-00Hospices Civils De Lyon132
招募中
1 期
Safety and effectiveness assessment of injectable suspension of Inshape x Radiance plus for the treatment of the back of hand wrinklesIRCT20150101020514N31ano Darou Pajouhan Pardis Company15
进行中（未招募）
不适用
ear Ifrared imaging of peritoneal metastasis of colon cancer origine.EUCTR2013-000653-42-BEJules Bordet Institute
进行中（未招募）
1 期
Feasibility study of the (intravenously injected) Indocyanine green (ICG) imaging of tumoral implants in patients with peritoneal carcinomatosis from ovarian carcinomaEUCTR2013-000276-15-BEJules Bordet Institute